PDE5A and pulmonary arterial hypertension: Pulmonary Arterial Hypertension: The guidelines recommend the use of bosentan, PDE-5 inhibitors, riociguat, intravenous epoprostenol, or other prostacyclin analogs for the treatment of systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH).